Argenica Therapeutics Limited
Argenica Therapeutics Limited (AGN.AX) Financial Performance & Income Statement Overview
Analyze Argenica Therapeutics Limited (AGN.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Argenica Therapeutics Limited (AGN.AX) Income Statement & Financial Overview
Analyze Argenica Therapeutics Limited’s AGN.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $1.42M | $1.42M | $122756.00 | $122756.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $1.42M | $1.42M | $122756.00 | $122756.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $1.46M | $1.46M | $1.60M | $1.60M |
| SG&A Expenses | $688768.00 | $688768.00 | $629052.00 | $629052.00 |
| Operating Expenses | $2.15M | $2.15M | $2.23M | $2.23M |
| Total Costs & Expenses | $2.15M | $2.15M | $2.23M | $2.23M |
| Interest Income | $0.00 | $0.00 | $140317.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $730168.00 | $730168.00 | $2.11M | $2.11M |
| EBITDA | $0.00 | $0.00 | -$1.96M | $0.00 |
| EBITDA Ratio | $0.00 | $0.00 | -$16.006 | $0.00 |
| Operating Income | -$730168.00 | -$730168.00 | -$2.11M | -$2.11M |
| Operating Income Ratio | -$0.52 | -$0.52 | -$17.15 | -$17.15 |
| Other Income/Expenses (Net) | $136557.00 | $136557.00 | -$1.96M | $70120.00 |
| Income Before Tax | -$593611.00 | -$593611.00 | -$4.07M | -$2.03M |
| Income Before Tax Ratio | -$0.42 | -$0.42 | -$33.15 | -$16.58 |
| Income Tax Expense | $0.00 | $0.00 | -$2.03M | $0.00 |
| Net Income | -$593611.00 | -$593611.00 | -$2.03M | -$2.03M |
| Net Income Ratio | -$0.42 | -$0.42 | -$16.58 | -$16.58 |
| EPS | -$0.005 | -$0.005 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.005 | -$0.005 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $128.09M | $126.30M | $107.70M | $107.70M |
| Weighted Avg Shares Outstanding (Diluted) | $128.09M | $126.30M | $108.15M | $108.15M |
Over the last four quarters, Argenica Therapeutics Limited achieved steady financial progress, growing revenue from $122756.00 in Q3 2024 to $1.42M in Q2 2025. Gross profit stayed firm with margins at 100% in Q2 2025 versus 100% in Q3 2024. Operating income totaled -$730168.00 in Q2 2025, maintaining a -52% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $0.00. Net income rose to -$593611.00, with EPS at -$0.005. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan